NEKTAR THERAPEUTICS Insider Trading Activity
Every SEC Form 4 insider transaction reported for NEKTAR THERAPEUTICS (NKTR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are NKTR insiders buying or selling?
In the last 12 months, NEKTAR THERAPEUTICS insiders reported 0 open-market purchases ($0) and 13 sales ($2.4M) — net selling of $2.4M. Since January 2018, Trabud has recorded 233 Form 4 filings for NKTR: 2 buys ($549.4K) and 231 sells ($155.7M).
Source: SEC EDGAR Form 4
What stands out
- No NEKTAR THERAPEUTICS insider made an open-market purchase in the last 12 months; the 13 reported open-market sales totaled $2.4M.
Key Statistics (January 2018 – Aug 20, 2026)
Total Form 4 filings
233
SEC EDGAR
Insider filers
19
Insider buys (2)
$549.4K
Insider sells (231)
$155.7M
Insider sentiment
Net sellingNet insider flow of $155.1M in net selling since January 2018, and $2.4M in net selling over the last 12 months.
Recent NKTR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 20, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sale | 186 | $71.98 | $13.4K | SEC ↗ |
| Aug 20, 2026 | Howard W Robin | President & CEO | Sale | 418 | $71.98 | $30.1K | SEC ↗ |
| Jul 2, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sale | 5.7K | $70.00 | $397.7K | SEC ↗ |
| Jun 18, 2026 | Howard W Robin | President & CEO | Sale | 20.0K | $60.75 | $1.2M | SEC ↗ |
| Jun 17, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sale | 5.5K | $60.71 | $336.2K | SEC ↗ |
| May 21, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sale | 199 | $65.51 | $13.0K | SEC ↗ |
| May 21, 2026 | Howard W Robin | President & CEO | Sale | 444 | $65.51 | $29.1K | SEC ↗ |
| Feb 21, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sale | 180 | $73.00 | $13.1K | SEC ↗ |
| Feb 21, 2026 | Howard W Robin | President & CEO | Sale | 423 | $73.00 | $30.9K | SEC ↗ |
| Jan 23, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sale | 3.9K | $35.67 | $137.9K | SEC ↗ |
| Nov 26, 2025 | Jonathan Zalevsky | Chief R&D Officer | Sale | 1.2K | $54.28 | $62.8K | SEC ↗ |
| Nov 26, 2025 | Mark Andrew Wilson | Chief Legal Officer | Sale | 630 | $54.28 | $34.2K | SEC ↗ |
| Nov 26, 2025 | Howard W Robin | President & CEO | Sale | 2.2K | $54.28 | $119.8K | SEC ↗ |
| Sep 12, 2025 | Howard W Robin | President & CEO | Sale | 6.7K | $46.69 | $311.2K | SEC ↗ |
| Sep 9, 2025 | Jonathan Zalevsky | Chief R&D Officer | Sale | 1.7K | $33.52 | $57.7K | SEC ↗ |
| Sep 9, 2025 | Howard W Robin | President & CEO | Sale | 11.8K | $36.42 | $431.0K | SEC ↗ |
| Sep 5, 2025 | Jonathan Zalevsky | Chief R&D Officer | Sale | 485 | $30.10 | $14.6K | SEC ↗ |
| Sep 5, 2025 | Howard W Robin | President & CEO | Sale | 1.5K | $30.16 | $45.2K | SEC ↗ |
| Aug 22, 2025 | Jonathan Zalevsky | Chief R&D Officer | Sale | 725 | $26.59 | $19.3K | SEC ↗ |
| Aug 22, 2025 | Mark Andrew Wilson | Chief Legal Officer | Sale | 676 | $26.59 | $18.0K | SEC ↗ |
| Aug 22, 2025 | Howard W Robin | President & CEO | Sale | 1.6K | $26.59 | $41.8K | SEC ↗ |
| May 22, 2025 | Jonathan Zalevsky | Chief R&D Officer | Sale | 10.7K | $0.67 | $7.2K | SEC ↗ |
| May 22, 2025 | Mark Andrew Wilson | Chief Legal Officer | Sale | 10.0K | $0.67 | $6.7K | SEC ↗ |
| May 22, 2025 | Howard W Robin | President & CEO | Sale | 23.2K | $0.67 | $15.5K | SEC ↗ |
| Feb 21, 2025 | Jonathan Zalevsky | Chief R&D Officer | Sale | 10.3K | $1.01 | $10.4K | SEC ↗ |
Showing the 25 most recent of 233 Form 4 filings for NEKTAR THERAPEUTICS.
Most active NKTR insiders
- Howard W Robin46 filings
- Jonathan Zalevsky36 filings
- Gil M Labrucherie26 filings
- Mark Andrew Wilson25 filings
- Jillian B. Thomsen24 filings
Ask anything about NKTR insider activity
Use Trabud's AI agent to query NEKTAR THERAPEUTICS's Form 4 history in plain English — "Show me NKTR CEO purchases this year" or compare it against any other ticker.
Open the AI agentNKTR insider trading FAQ
Are NEKTAR THERAPEUTICS insiders buying or selling?
In the last 12 months, NEKTAR THERAPEUTICS insiders reported 0 open-market purchases ($0) and 13 sales ($2.4M) — net selling of $2.4M. Since January 2018, Trabud has recorded 233 Form 4 filings for NKTR: 2 buys ($549.4K) and 231 sells ($155.7M). Over the full record that is net selling of $155.1M.
How many insiders trade NKTR stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for NEKTAR THERAPEUTICS. The most recent filing was accepted on Aug 20, 2026.
Where does Trabud get NKTR insider trading data?
All NKTR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.